| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.2013.842975 |
| P8608 | Fatcat ID | release_fam73eh2bzferbqjch2b6qmduu |
| P698 | PubMed publication ID | 24073999 |
| P50 | author | Soldano Ferrone | Q90626068 |
| Francesco Sabbatino | Q42325106 | ||
| P2093 | author name string | Xinhui Wang | |
| Cristina R Ferrone | |||
| Yangyang Wang | |||
| P2860 | cites work | Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions | Q21004109 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells | Q24606438 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum | Q26860153 | ||
| Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance | Q26866517 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial | Q27851852 | ||
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression | Q28269191 | ||
| Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance | Q28282963 | ||
| B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts | Q28508452 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| MAP kinase signalling pathways in cancer | Q29615542 | ||
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization | Q30443185 | ||
| Positive phase II study in the treatment of advanced malignant melanoma with fotemustine | Q33374887 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway | Q33968056 | ||
| Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management | Q33984859 | ||
| BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice | Q33996674 | ||
| Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells | Q34069302 | ||
| The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms | Q34165045 | ||
| gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma | Q34188859 | ||
| CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma | Q34299986 | ||
| Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 | ||
| Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS | Q34545490 | ||
| Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c | Q34600089 | ||
| Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). | Q34629364 | ||
| Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study | Q34652628 | ||
| A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma | Q34710725 | ||
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 | ||
| Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition | Q35146471 | ||
| Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF | Q35700459 | ||
| Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies | Q35859282 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| Raf: a strategic target for therapeutic development against cancer | Q36260492 | ||
| Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival | Q37028555 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas | Q37118264 | ||
| Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. | Q37149695 | ||
| TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma | Q37401151 | ||
| Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. | Q37697383 | ||
| Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy | Q37734285 | ||
| CSPG4 in cancer: multiple roles | Q37747536 | ||
| Melanoma as a model tumour for immuno-oncology | Q38037486 | ||
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 | ||
| Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma | Q39304634 | ||
| Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated byNRASorMEKMutations | Q39385617 | ||
| The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells | Q39515657 | ||
| Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. | Q39610715 | ||
| PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas | Q39640222 | ||
| RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | Q39692674 | ||
| Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function | Q39692699 | ||
| Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. | Q39712781 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells | Q40262620 | ||
| B-RAF is a therapeutic target in melanoma | Q40543086 | ||
| Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. | Q40662652 | ||
| Paradoxical activation of Raf by a novel Raf inhibitor | Q40939473 | ||
| BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer | Q42417533 | ||
| Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma | Q43693202 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Mutant B-RAF mediates resistance to anoikis via Bad and Bim. | Q46774780 | ||
| BRAF alterations are associated with complex mutational profiles in malignant melanoma | Q47349130 | ||
| Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | Q47573472 | ||
| Meeting report from the 2011 International Melanoma Congress, Tampa, Florida | Q53141067 | ||
| Multidisciplinary approach to patient with malignant melanoma | Q54462557 | ||
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 | ||
| Melanoma | Q56428909 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 431-443 | |
| P577 | publication date | 2013-09-27 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging BRAF inhibitors for melanoma | |
| P478 | volume | 18 |
| Q35811459 | Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells |
| Q54964481 | KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature. |
| Q35773340 | Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis |
Search more.